contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magle-chemoswed-holding-reports-financial-results-for-fourth-quarter-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.

Magle Chemoswed Holding

Magle Group’s Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment.Q4 2025 KEY INDICATORSNet Sales amounted...

<div class="mfn-preamble"><p><strong>Magle Group’s Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment.</strong></p></div><div class="mfn-body"><p><strong>Q4 2025 KEY INDICATORS</strong></p><ul><li>Net Sales amounted to 77.7 MSEK (87.2)</li><li>EBITDA equaled -58.5 MSEK (20.0)</li><li>Operating profit (EBIT) is -120.3 MSEK (3.9)</li><li>Earnings per share SEK -6.49 (-0.04) per share</li></ul><p><strong>JAN-DEC 2025 KEY INDICATORS</strong></p><ul><li>Net Sales amounted to 282.9 MSEK (236.0)</li><li>EBITDA equaled -26.5 MSEK (58.9)</li><li>Operating profit (EBIT) is -126.7 MSEK (23.2)</li><li>Earnings per share SEK -7.74 (0.93) per share</li></ul><p>“Our priority is to sharpen the Group’s business focus and improve profitability by directing resources towards the parts of the business where we see the strongest commercial traction and most predictable returns. The adjustments made during the quarter form part of an ongoing clean-up of the portfolio and cost structure, aimed at reducing complexity and improving capital efficiency. While these measures impact the short-term financial outcome, they are necessary steps in building a more focused and financially sustainable organisation.”</p></div><div class="mfn-footer mfn-contacts mfn-c123be755a9c"><p><strong class="mfn-heading-1">Contacts Aaron</strong></p><hr><p>Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com</p></div><div class="mfn-footer mfn-about mfn-70935ab259f1"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on&nbsp;<strong><a href="http://www.maglechemoswed.com/" rel="noopener">www.maglechemoswed.com</a></strong> and <strong><a href="https://maglegroup.com/" rel="noopener">www.maglegroup.com</a></strong><strong> </strong>and <strong><a href="http://www.maglepharmacept.com" rel="noopener">www.maglepharmacept.com</a></strong><strong> </strong>and <strong><a href="https://maglebiopolymers.com/" rel="noopener">www.maglebiopolymers.com</a></strong><br>Redeye Nordic Growth AB is the company's Certified Adviser.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-27 08:30 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a class="mfn-primary" href="https://storage.mfn.se/27e5067c-fded-4870-bd6c-e82b2b8973c0/q4-interim-report-2025-final.pdf" rel="noopener">Q4 Interim Report 2025 Final</a></p></div>